Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31497879)

  • 1. Family history is significantly associated with prostate cancer and its early onset in Chinese population.
    Xu Y; Huang D; Wu Y; Ye D; Zhang N; Gao Y; Xu D; Na R; Xu J
    Prostate; 2019 Nov; 79(15):1762-1766. PubMed ID: 31497879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between family history of prostate cancer and positive biopsies in a Brazilian screening program.
    Muller RL; Faria EF; Carvalhal GF; Reis RB; Mauad EC; Carvalho AL; Freedland SJ
    World J Urol; 2013 Oct; 31(5):1273-8. PubMed ID: 22820620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy?
    Elshafei A; Moussa AS; Hatem A; Ethan V; Panumatrassamee K; Hernandez AV; Jones JS
    Urology; 2013 Apr; 81(4):826-30. PubMed ID: 23434102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
    Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
    BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
    Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic characteristics and prognosis of early onset prostate cancer].
    Wang Y; Du SJ; Zhang JX; He HY
    Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):373-377. PubMed ID: 28591982
    [No Abstract]   [Full Text] [Related]  

  • 13. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
    Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
    BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
    Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
    Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
    Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen.
    Gao HW; Li YL; Wu S; Wang YS; Zhang HF; Pan YZ; Zhang L; Tateno H; Sato I; Kuwahara M; Zhao XJ
    Asian J Androl; 2005 Jun; 7(2):159-63. PubMed ID: 15897972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
    Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
    BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.
    Chen YC; Page JH; Chen R; Giovannucci E
    Prostate; 2008 Oct; 68(14):1582-91. PubMed ID: 18646000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.